Posted on

Ferrand-Prévot and Carod win short track events at Val di Sole MTB World Cup

Ferrand-Prévot and Carod win short track events at Val di Sole MTB World Cup

The final round of the first-ever World Cup season in the cross-country Short Track (XCC), saw world champion Pauline Ferrand-Prévot (BMC) win the women’s race and her BMC teammate Titouan Carod win the men’s on Friday, in Val di Sole, Italy. 

The first overall series titles went to Alessandra Keller (Thomus Maxon) and Alan Hatherly (Cannondale Factory).

The women’s 20-minute race quickly came down to four riders – Ferrand-Prévot, Keller, Loana Lecomte (Canyon Collective) and Olympic XCO champion Jolanda Neff (Trek Factory).

Posted on

Rissveds, Colombo win Lenzerheide World Cup short track events

Rissveds, Colombo win Lenzerheide World Cup short track events

Jenny Rissveds won the fifth stop of the Short Track (XCC) series in Lenzerheide, Switzerland on Friday. The Swede held off the strong Swiss duo of Alessandra Keller and Jolanda Neff in picture-perfect conditions in Switzerland, which was held on a one-kilometre course around the Bike Arena. 

“Lenzerheide is quite similar to Sweden. Many roots. I like that. I didn’t really have a strategy, but found I was the fastest through the root passages, so I just went for it. I just found a good balance in my life. I’m happy and I love cycling and I enjoy racing too. It can go on like this,” Rissveds said after the UCI MTB World Cup victory, her third podium of the year in short track.

Posted on

2022 WSOP Main Event Falls Just Short of Record-Breaking Attendance

2022 WSOP Main Event Falls Just Short of Record-Breaking Attendance
2022 wsop main event

Many projected a record-breaking year for the 2022 World Series of Poker Main Event, some even anticipating 10,000 or more players. But when registration officially closed around 4 p.m. on Friday, the 2006 record of 8,773 entries still stood.

With 8,663 entrants, this year’s world championship event is officially the second largest in the tournament’s 53-year history, slightly higher than the 8,569 of 2019. The winner on July 17 will take home $10 million, with second place receiving $6 million.

Gold Holds onto Record

Jamie Gold
Jamie Gold

Jamie Gold, who didn’t compete in the 2022 Main Event, can still stake his claim to having won the largest Main Event of all-time. In 2006, during the height of the poker boom, he defeated a massive field en route to a $12 million payday, also the largest cash in any WSOP event not named the $1 million Big One for One Drop.

It may come as a bit of a surprise, but Gold was rooting for the record to not only be broken, but to be “smashed.” And he thought it should have been years ago.

“I’ve been looking forward to seeing a larger field in the main event since I was lucky enough to play in my first that happened to have the largest field,” Gold told PokerNews. “If not for a ridiculous law that in effect shut down US online poker in 2007, I believe there would be 25,000 entrants or more by now, then hopefully without having to add the Day 2 buy in option.”

“The amount of players sponsored and winning satellites combined with the expansion of at least 38 states playing in mutual pools would have been wonderful to see. I believe the game and community I care about deeply is still growing and will continue to expand as states legalize and the next generation of players discover new ways of playing and more variants. Either way, that number will be surpassed next year finally and I look forward to getting back to playing again. Was very sad to miss it this year.”

Prior to the start of the World Series of Poker, the PokerNews crew made some predictions on Main Event attendance, all of which weren’t too far off base, except for Matthew Pitt, who projected an underwhelming 7,294 entries. Five out of 10 of us predicted a record-breaking Main Event.

Top 10 Largest WSOP Main Events in History

Year Entrants Winner
2006 8,773 Jamie Gold
2022 8,663 ?
2019 8,569 Hossein Ensan
2018 7,874 John Cynn
2010 7,319 Jonathan Duhamel
2011 6,865 Pius Heinz
2008 6,844 Peter Eastgate
2016 6,737 Qui Nguyen
2014 6,683 Martin Jacobson

Long Lines Frustrate Players

Registration remained open until the start of Level 8 on Day 2d, two 120-minute levels into the session. Hundreds of players late registered before play began on Friday but were stuck in a huge line that wrapped around the Bally’s ballroom, some even had to wait up to two hours just to get into a game.

PokerNews was approached by multiple frustrated players in line who were angry with the wait times. But there simply weren’t seats available until players busted, according to a floor manager we spoke with.

Each player started with 60,000 chips regardless of when they first took a seat. At the start of Day 2, the blinds were at 400-800, meaning the first players in line would begin with a healthy stack of 75 big blinds. Those who were last to enter the tournament started with 50 big blinds.

Follow the 2022 WSOP Main Event on PokerNews

Posted on

Meta-analysis: Testosterone treatment not linked to short-, medium-term CV events in men

Graphical depiction of data presented in article

Hudson reports no relevant financial disclosures. Please see the study for all other authors’ relevant financial disclosures.

We were unable to process your request. Please try again later. If you continue to have this issue please contact

In men with hypogonadism, there was no evidence that testosterone treatments cause short-term or medium-term CV risks, according to a meta-analysis published in The Lancet Healthy Longevity.

There were not enough data to conclude anything about the relationship between testosterone treatments and long-term CV risks, according to the researchers.

Graphical depiction of data presented in article

Source: Adobe Stock

“Prescribing of testosterone for hypogonadism is increasing globally, but conflicting messages about its safety may have led to many patients not receiving the treatment,” Jemma Hudson, MSc, from the Health Services Research Unit at the University of Aberdeen, United Kingdom, said in a press release. “Ongoing studies should help to determine the longer-term safety of testosterone, but in the meantime, our results provide much-needed reassurance about its short- to medium-term safety. Our findings could have important implications for the treatment of men with hypogonadism worldwide.”

Hudson and colleagues conducted a meta-analysis of 35 studies of trials of testosterone vs. placebo for hypogonadism including 5,601 participants (mean age, 65 years). Of those studies, 17 comprising 3,431 participants with a mean follow-up of 9.5 months had individual participant data. The researchers performed a one-stage meta-analysis of the individual participant data and a two-stage meta-analysis integrating individual participant data with the studies that did not provide it.

All-cause deaths were numerically lower in the testosterone group but were too few to determine statistical significance (0.4% vs. 0.8%; OR = 0.46; 95% CI, 0.17-1.24; P = .13), according to the researchers.

The rate of CV events was similar in both groups (testosterone, 7.5%; placebo, 7.2%; OR = 1.07; 95% CI, 0.81-1.42; P = .62), Hudson and colleagues wrote.

The most frequently occurring CV events were arrhythmia, CHD, HF and MI, all of which occurred at similar rates in both groups, according to the researchers.

There was no difference in CV risk by age (P for interaction = .17), baseline testosterone level (P for interaction = .69), smoking status (P for interaction = .35) and diabetes status (P for interaction = .025), the researchers wrote.

“An important strength of this [individual participant data] meta-analysis is its large size compared with individual testosterone trials, which have provided limited and situation-dependent information on cardiovascular safety,” Hudson and colleagues wrote. “This study has allowed us to more precisely estimate the incidence of cardiovascular events associated with testosterone treatment, which might be generalizable to patients worldwide.”


  • Little evidence testosterone treatment increases the risk of cardiovascular events, most in-depth analysis suggests. Published June 8, 2022. Accessed June 9, 2022.